Clinical Trial â Effect of Secukinumab in PsA â Psoriasis Arthritis
The study is designed to investigate, in detail, the clinical and molecular effects of secukinumab(Cosentyx) in the treatment of Psoriasis Arthritis.
The investigators will also make use of the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab.
| Study Type : | Interventional  (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Basic Science |
| Official Title: | An Exploration of the Dynamic Interaction Between IL-17, IL-17 Inhibition With (Secukinumab) and Neutrophils in Psoriatic Arthritis in Vitro and ex Vivo With Exploratory Study on the Potential Role of Vitamin D |
| Study Start Date : | October 2016 |
| Estimated Primary Completion Date : | August 2018 |
| Estimated Study Completion Date : | August 2018 |
| Contacts | |||
|---|---|---|---|
| Contact: Laurence S Loubiere, PhD | loubiere@liverpool.ac.uk |
| ClinicalTrials.gov Identifier: | NCT02854163 |
For enrollment please visit www.clinicaltrials.gov.
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.